Mirum Pharmaceuticals price to book ratio MIRM

Market value divided by the book value of the company's net assets, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 26.6×; Jul 2026
7-year median: 6.7×
7-year range: 1.1× to 31.6×
Peer median: 10.6×

Mirum Pharmaceuticals' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Jul 2026, at 26.6×.

On the days it had one over the last 7 years, its median was 6.7×, from 1.1× in Nov 2019 to 31.6× in Jul 2026.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.6×	13.7×	31.6×
2025	13.9×	8.5×	15.0×
2024	8.6×	4.5×	9.6×
2023	5.1×	4.3×	16.0×
2022	4.2×	4.0×	12.8×
2021	8.7×	3.2×	8.7×
2020	3.7×	2.2×	5.4×
2019	4.1×	1.1×	4.1×

Against its peers

Companies in Drug Manufacturers - General nearest Mirum Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
MIRMMirum Pharmaceuticals	n/m
KNSAKiniksa Pharmaceuticals International	9.2×
LGNDLigand Pharmaceuticals	6.3×
AMRXAmneal Pharmaceuticals	197×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	17.8×
LQDALiquidia	19.6×
ALKSAlkermes plc.	4.0×
OGNOrganon	3.6×
TGTXTG Therapeutics	13.7×
PTGXProtagonist Therapeutics	10.6×
Peer median	10.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Mirum Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.